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1 Abstract
Early detection of clinical outcomes such as cancer may be predicted based on
longitudinal biomarker measurements. Tracking longitudinal biomarkers as a way to
identify early disease onset may help to reduce mortality from diseases like ovarian
cancer that are more treatable if detected early. Two general frameworks for disease risk
prediction, the shared random effects model (SREM) and the pattern mixture model
(PMM) could be used to assess longitudinal biomarkers on disease early detection. In
this paper, we studied the predictive performances of SREM and PMM on disease early
detection through an application to ovarian cancer, where early detection using the risk
of ovarian cancer algorithm (ROCA) has been evaluated. Comparisons of the above
three methods were performed via the analyses of the ovarian cancer data from the
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and extensive
simulation studies. The time-dependent receiving operating characteristic (ROC) curve
and its area (AUC) were used to evaluate the prediction accuracy. The out-of-sample
predictive performance was calculated using leave-one-out cross-validation (LOOCV),
aiming to minimize the problem of model over-fitting. A careful analysis of the use of
the biomarker cancer antigen 125 for ovarian cancer early detection showed improved
performance of PMM as compared with SREM and ROCA. More generally, simulation
studies showed that PMM outperforms ROCA unless biomarkers are taken at very
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1
ar
X
iv
:1
90
8.
08
09
3v
1 
 [s
tat
.A
P]
  2
1 A
ug
 20
19
frequent screening settings.
Keywords: Disease early detection prediction; pattern mixture model; risk of ovarian
cancer algorithm; shared random effects model; time-dependent AUC
1 Introduction
Epidemiologic studies usually incorporate longitudinal biomarkers into the prediction of clin-
ical outcomes. Early disease detection could also benefit from this approach, since additional
information on critical time point and pathology is often contained in the subject-specific
biomarker trajectories (Drescher et al., 2013; Menon et al., 2015; Han and Liu, 2019). Track-
ing longitudinal biomarkers in a population may result in earlier disease detection and may
help to reduce mortality from diseases that are more treatable if detected early (McIntosh
and Urban, 2003). One example is ovarian cancer, which is the fifth leading cause of cancer-
related deaths among the U.S. women and one of the most lethal gynecological cancers
(Skates et al., 2003; Zhang et al., 2004; Clarke-Pearson, 2009; Henderson et al., 2018; Rus-
sell et al., 2017). Ovarian cancer usually has no symptoms at its early stage and develops
undetected until it has spread within the pelvis and abdomen (Matulonis et al., 2016). The
U.S. ovarian cancer survival statistics show that the 5-year survival rate for women with late
stage ovarian cancer is only 29.2% (23% in the U.K.), in contrast to 92.4% (about 90% in the
U.K.) for those diagnosed at an early stage (Howlader et al., 2019; Russell et al., 2017). Al-
though early stage ovarian cancer can be treated with a higher success rate (Clarke-Pearson,
2009), the majority of ovarian cancer cases are diagnosed at late stage, when curative treat-
ment rarely exists, making methods for the detection of early stage ovarian cancer desirable
(Skates et al., 2017). However, large randomized trials have not shown a survival benefit for
current early detection approaches of ovarian cancer so far (Pinsky et al., 2013; Wentzensen,
2016).
When the interest is to use longitudinal biomarker information to predict a subsequent bi-
nary outcome, good modeling of the longitudinal biomarker trajectories is often the key to
obtain accurate outcome prediction. However, in the prediction of ovarian cancer early de-
tection, there is not much research to investigate how the different strategies of modeling the
biomarker trajectories would affect the prediction accuracy under the longitudinal setting.
Besides, a comparison of the different techniques is complicated, in part because it may
depend on the screening frequency of the biomarker.
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The risk of ovarian cancer algorithm (ROCA) has been proposed for ovarian cancer early
detection using repeatedly measured serum biomarker cancer antigen 125 (CA-125) values
(Skates et al., 2001). Specifically in the model setting, ROCA separately models the lon-
gitudinal CA-125 trajectories for the cases and the controls. For the controls, a constant
mean model of CA-125 is assumed with a random intercept term that accounts for subject
heterogeneity. For the cases, the CA-125 trajectory is assumed to be piecewise linear with
a latent subject-specific changepoint. The probability of early detection is then constructed
using Bayes’ theorem.
Recently, two general frameworks for disease risk prediction by modeling longitudinal biomarker
behaviors have been developed. The shared random effects model (SREM) (Albert, 2012)
predicts a binary outcome based on the longitudinal biomarkers by assuming a shared ran-
dom effects structure that links the binary outcome and the longitudinal process together,
while the pattern mixture model (PMM) (Liu and Albert, 2014) fits the biomarker distribu-
tions conditional on the binary outcome and then constructs the outcome prediction using
Bayes’ theorem. SREM and PMM are originally proposed for disease risk prediction us-
ing serial biomarker values and associated observation times (Han and Liu, 2019; Liu and
Albert, 2014), but can be applied more generally to predict disease early detection in the
longitudinal setting.
In this paper, we focused on examining and evaluating the utility of SREM and PMM for
disease early detection through an application to ovarian cancer, under which SREM and
PMM were compared with ROCA. Comparisons of SREM and PMM with ROCA were per-
formed via simulation studies and an empirical analysis of the ovarian cancer data from the
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Specifically, we
first extended ROCA to identify the potential effects of the baseline age and the screen-
ing time on the marker trajectories and then proposed a maximum-likelihood approach for
parameter estimation. Specific formulations of SREM and PMM for predicting the early
detection of ovarian cancer were also proposed. Modeling forms under SREM, PMM, and
ROCA for the longitudinal CA-125 trajectories in the PLCO Cancer Screening Trial were
compared and their effects on the prediction accuracy of ovarian cancer early detection were
further assessed. The predictive performances of different models were evaluated by the
time-dependent receiving operating characteristic (ROC) curve and its area (AUC) (Hea-
gerty et al., 2000), such that the right censored cancer diagnosis times can be incorporated
into the AUC calculation. Previous studies, to the contrary, simply used an ordinary ROC
3
curve to examine the accuracy of ROCA (Russell et al., 2017) by treating the ovarian cancer
outcome as binary and hence ignored the diagnosis time information. Furthermore, to es-
timate the out-of-sample prediction accuracy, we applied the leave-one-out cross-validation
(LOOCV) technique to minimize the problem of model overfitting (Russell et al., 2017;
Berchuck et al., 2005). In addition, to check the effects of biomarker measuring frequency
on the prediction accuracy of SREM, PMM, and ROCA regarding ovarian cancer early de-
tection, we considered three screening frequencies (annual, biannual, and quarterly) in the
simulation studies. Our research answered the questions about the effects of using SREM,
PMM, and ROCA as well as the effects of different screening frequencies on the prediction
accuracy of ovarian cancer early detection.
The rest of this paper is organized as follow: Section 2 briefly reviews the general settings
of the SREM and PMM frameworks. Section 3 first introduces the problem of predicting
the ovarian cancer early detection and reviews ROCA. Potential issues of ROCA are pointed
out and several extensions are then proposed. In the end, the formulations of SREM and
PMM tailored for predicting ovarian cancer early detection are specified. We compare the
prediction performances of PMM, SREM, and ROCA in Section 4 through an application
to the PLCO ovarian cancer trial and perform additional simulation studies in Section 5.
Section 6 ends this study with a discussion.
2 Review of Methods
In this section, we review the SREM and the PMM frameworks. Without loss of generality,
let Yij denote the biomarker value for the ith individual at time tij, where i = 1, 2, . . . , N , N
is sample size, j = 1, 2, . . . , ni, and ni is the number of longitudinal biomarker measurements
for the ith participant. Without loss of generality, assume the first M subjects are cases and
the rest N −M are controls. Let Di be the binary outcome, such that Di = 1 indicates a
case and Di = 0 denotes a control.
2.1 Shared Random Effects Model (SREM)
SREM jointly models the longitudinal biomarker trajectories and the binary disease outcomes
(Albert, 2012), which are assumed to share the same set of random effects. For the case and
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the control trajectories, a linear mixed model was proposed
Yi = Xiθ +Zibi + ξi (1)
where Xi and Zi are design matrices of the fixed and the random covariates, θ are the fixed
effects, bi stand for the random effects, and ξi ∼MVN(0,Σξ) are the random measurement
errors. The relation between Di and bi is given as
P (Di = 1|bi) = g
{
α0 +α
>
1 h(bi)
}
(2)
where g(·) is a link function and h(·) is a function of random effects. In the simulation
studies and the real data analyses, we set α>1 h(bi) to be α1bi0 + α2bi1 + α3bi2 + α4bi3, so
each random effect would affect the disease outcome differently. The strength of association
between the longitudinal process and the binary outcome is quantified by α1, while α0 is the
intercept.
As SREM gives the distributions of Yi|bi and Di = 1|bi, the joint distribution of Yi and Di
can be derived by integrating over the random effects bi. The diagnosis probability thus can
be calculated from the joint distribution of Yi and Di as
P (Di = 1|Yi) =
∫
P (Yi|bi)P (Di = 1|bi)f(bi)dbi∫
P (Yi|bi)f(bi)dbi (3)
where f(bi) is the probability density function (PDF) of bi. If a probit link function is
used and bi ∼ MVN(0,Σb), Albert (2012) revealed that the SREM estimation can be
substantially simplified by decomposing the joint likelihood function of Di and Yi as
L = L1 × L2 =
N∏
i=1
f(Yi)
N∏
i=1
f(Di|Yi) (4)
where L1 is from the longitudinal process in (1) and L2 has an explicit expression
P (Di = 1|Yi) = Φ
{
α0 +α1h(bi)√
1 +α>1 Cov(h(bi))α1
}
(5)
Parameters in (1) are estimated by maximizing L1, while α0 and α1 in (2) are estimated by
maximizing L2, given the estimates from L1. The probability is then obtained by replacing
the parameters in (5) with their maximum likelihood estimates (MLEs).
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2.2 Pattern Mixture Model (PMM)
PMM directly makes the assumption of a linear mixed model on the biomarker trajectories
conditional on the binary outcome, i.e., Yi|Di = d, d = 0, 1. In other words, PMM formu-
lates the longitudinal behaviors for the diseased and non-diseased subjects separately. With
normal random effects and error terms, Yi|Di follows a multivariate normal distribution
Yi|Di ∼MVN(µd,Γd) (6)
where the means vectors and the covariance matrices are both functions of the covariates.
The linear mixed models can be easily estimated from standard statistical software packages.
Then the probability P (Di = 1|Yi) can be obtained using Bayes’ rule
P (Di = 1|Yi)
P (Di = 0|Yi) =
P (Yi|Di = 1)
P (Yi|Di = 0) ×
P (Di = 1)
P (Di = 0)
(7)
where P (Di = d) is the prior information that is often known or can be estimated from the
empirical data. The likelihood ratio P (Di = 1|Yi)/P (Di = 0|Yi) under PMM is shown to
be the optimal combination of the longitudinal biomarkers, provided that P (Yi|Di = d) can
be accurately estimated (Liu and Albert, 2014).
PMM and SREM derive the disease risk prediction as an implicit function of the biomarkers
and their observation time, and can be applied more generally, for instance, to disease early
detection. It has been shown that PMM is a close approximation to SREM but the converse
is not true: if SREM is the true data generation model, both PMM and SREM would have
similar performances; but if PMM is the truth, SREM generally results in sub-optimal risk
prediction (Liu and Albert, 2014; Han and Liu, 2019).
3 Methods for ovarian cancer early detection
Early disease detection may help to prevent death from diseases like cancer that are more
curable at early stage. It is especially true for ovarian cancer, which rarely has curative
treatment when detected at late stage. Good modeling of the biomarker trajectories is
usually the key to accurate detection prediction. To understand the unique feature of ovarian
cancer biomarker trajectories, we considered samples from the PLCO Cancer Screening Trial,
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where the biomarker cancer antigen 125 (CA-125) was studied for screening. Trajectories
of the log-transformed CA-125 of 50 cases (women from the intervention arm of the trial
who developed ovarian cancer during the screening) and 50 controls (those who did not but
were also from the intervention arm of the trial so CA-125 levels were available) that were
randomly selected from the PLCO Cancer Screening Trial are shown in Figure 1. The CA-
2
4
6
8
0 2 4
Screening Time (Year since trial randomization)
lo
g(
C
A
-1
25
)
PLCO Case CA-125 Trajectory
2
4
6
8
0 2 4
Screening Time (Year since trial randomization)
lo
g(
C
A
-1
25
)
PLCO Control CA-125 Trajectory
Figure 1: CA-125 trajectories of 50 cases and 50 controls that were randomly selected from
the PLCO cancer screening trial
125 trajectories for cases may be either flat or stay flat at first and then jump up at some
time point during the screening. As a contrast, the control trajectories do not jump up and
almost always keep flat. The special patterns in the case and the control trajectories require
advanced modeling strategies for the CA-125 behaviors.
In this section, we first review a well-studied approach that has been proposed for ovarian
cancer early detection, namely the risk of ovarian cancer algorithm (ROCA). We then extend
ROCA to identify the potential effects of the baseline age and the screening time on the
biomarker trajectories and developed a maximum-likelihood approach for ROCA parameter
estimation. We further propose a PMM and a SREM specifically for ovarian cancer early
detection prediction.
Under the setting of ovarian cancer early detection, Yij denotes the natural logarithm trans-
formed CA-125 measurement for the ith woman at time tij (years since trial randomization).
The time Ti is the cancer diagnosis time for a case subject and the censored follow-up time
for a control subject.
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3.1 Risk of Ovarian Cancer Algorithm (ROCA)
As a method specifically developed for predicting ovarian cancer early detection, ROCA
separately models the longitudinal CA-125 trajectories for the cases and controls (Skates
et al., 2001). For the averaged case CA-125 trajectory, a piecewise linear model with a latent
subject-specific changepoint τi conditional on the diagnosis time Ti is assumed. The mean
for cases with elevated CA-125 after τi is
E(Yij|Di = 1, Ti) = θi + γi(tij − τi)+
The slope of increase after τi is denoted as γi, θi is a subject-specific random intercept, and
(x)+ = x when x > 0 and 0 otherwise. Skates et al. (2001) assumed that the changepoint τi
follows a known truncated normal distribution N[Ti−5,Ti](Ti− 2, 0.752) conditional on Ti. For
cases without elevated CA-125, the mean is
E(Yij|Di = 1, Ti) = θi
As for controls, a constant mean model
E(Yij|Di = 0) = θi
is assumed due to the flat CA-125 behaviors.
Parameter estimation of ROCA was implemented using the Bayesian framework. As for
the ovarian cancer detection prediction, ROCA also calculates the detection probability
P (Di = 1|Yi) using the Bayes’ rule in (7) but slightly differs from PMM. The difference will
be discussed in Section 3.2.
3.2 Extended ROCA
The piecewise linear model for cases under ROCA can be rewritten as
Yij = θ0 + γ0(tij − τi)+ + b0i + b1i(tij − τi)+ + ξij (8)
where θi is decomposed into a constant intercept θ0 and a random one b0i, and γi is decom-
posed into a constant rate γ0 and a random slope b1i. Random effects bi = (b0i, b1i)> ∼
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MVN(0,Σb). This model depicts that the CA-125 trajectory is flat before the changepoint,
and then increases with a slope of γ0 + b1i after the changepoint. For case subjects without
observed changepoint during the screening, the term (tij − τi)+ is just 0, leading to a flat
trajectory Yij = θ0 + b0i + ξij. Similarly, the ROCA control model can be rewritten as a
random intercept model
Yij = θ0 + b0i + ξij (9)
For easy presentation, denote the case model (8) as Case Model 1 (CS1) and the control
model (9) as Control Model 1 (CN1).
Several issues of ROCA requires attention: (i) the changepoint τi follows an assumed known
truncated normal distribution, which may not be reasonable for all study populations; (ii)
CN1 ignores the potential effects of the baseline age and the screening time on the CA-125
trajectories, inducing potentially biased inferences; (iii) the detection probability calculation
may suffer loss of accuracy. Theoretically, when predicting the cancer detection of a new
subject k, ROCA calculates the probability P (Dk = 1|Yk) using the formula in (7). How-
ever, ROCA only obtains an approximation of P (Yk|Dk = 1), say P˜ (Yk|Dk = 1), since it
models Yk|Dk = 1, Tk rather than Yk|Dk = 1. Calculating P˜ (Yk|Dk = 1) requires ROCA to
marginalize over the diagnosis time Tk, which is frequently unknown for the new individual
k. To get the approximated probability P˜ (Yk|Dk = 1), ROCA essentially implements the
marginalization by “borrowing” information about the diagnosis time from participants who
have already been known as cases via below formula
P˜ (Yk|Dk = 1) = 1
M
M∑
i=1
P (Yk|Dk = 1, Tk = tknk +Gi)
whereM is the number of known cases, the gap time Gi = Ti−tini , Ti is the cancer diagnosis
time for the ith known case, whose last screening time is tini , and tknk is the last screening
time of the new individual k. This marginalization eventually leads to
P (Dk = 1|Yk)
P (Dk = 0|Yk) ∝
P˜ (Yk|Dk = 1)
P (Yk|Dk = 0)
which may result in loss of prediction accuracy (as we observed this in simulation studies
later), especially when the sample size of known cases is relatively small.
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To address the above mentioned issues, we propose to extend the original ROCA in the
following ways:
(i) Instead of being prespecified, the parameters of the changepoint distribution are es-
timated, i.e., τi ∼ N(Ti − µτ , σ2τ ). Denote the case model (8) with this unspecified
changepoint distribution as Case Model 2 (CS2).
(ii) The control CA-125 trajectory is characterized by a linear mixed model that adjusts
for the screening time
Yij = θ0 + θ1tij + b0i + b1itij + ξij (10)
Denote this model as Control Model 2 (CN2).
(iii) As an alternative to (ii), the control trajectory is depicted by a linear mixed model
adjusting for both the screening time and the baseline age
Yij = θ0 + θ1tij + θ2Agei + b0i + b1itij + ξij (11)
Denote this model as Control Model 3 (CN3).
Different from the Bayesian strategy in Skates et al. (2001), we propose a maximum-likelihood
approach for the parameter estimation. The likelihood function f(yij|tij, Ti,ϑ) can be ob-
tained by integrating f(yij|tij, Ti, τi,ϑ) in (8) over the changepoint τi
f(yij|tij, Ti,ϑ) =
∫
f(yij|tij, Ti, τi,ϑ)g(τi)dτi
For CS1, parameters are ϑ = (θ0, γ0, σb0 , σb1 , ρb0b1 , σξ)> and g(τi) is the PDF of τi specified
by the truncated normal distribution. As for CS2, ϑ = (θ0, γ0, σb0 , σb1 , ρb0b1 , σξ, µτ , στ )>
and g(τi) is the PDF specified in CS2. The above integration with respect to the latent
changepoint could be numerically approximated by using the Gauss-Hermite quadrature. To
the contrary, all of the three control models can be easily estimated from standard software
packages, such as the R package nlme. Related R codes for the parameter estimation are
given in the Supplementary Material.
Combinations of case and control models lead to different versions of ROCA, denoted by
ROCA-CS1-CN1 (the original ROCA), ROCA-CS1-CN2, ROCA-CS1-CN3, ROCA-CS2-
CN1, ROCA-CS2-CN2, and ROCA-CS2-CN3, respectively.
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3.3 PMM for Ovarian Cancer
In this section, we propose a PMM such that the case model does not rely on the latent
changepoint structure. More specifically, we formulated the averaged case trajectory using
a linear mixed model with natural cubic splines to account for the effects of the screening
time and the baseline age. The case model under PMM is given as
Yij = θ0 +
3∑
`=1
θ`B`(Agei, λ) + b0i +
3∑
`=1
(θ`+3 + b`i)B`(tij, λ) + ξij (12)
where B`(x, λ) is the B-spline basis of order 3 for the natural cubic spline with knot λ decided
based on x, θ0, θ`, and θ`+3 are the fixed effects, b0i and b`i are the random effects, and ξij is
the random measurement error. For Agei, the boundary knots were the minimum and the
maximum of the baseline age of all cases, while the two internal knots were respectively set
as the first and the third quantiles of all cases’ baseline age. The knots for the screening time
were determined in the same way. As for the averaged control trajectory, we used control
models CN1, CN2, and CN3. PMM then predicts the ovarian cancer diagnosis using the
formula shown in (7). Denote the three versions of PMM as PMM-CN1, PMM-CN2, and
PMM-CN3.
As ROCA separately models the case and the control trajectories, it can be regarded as a
special case of the PMM framework. However, there are two key differences between PMM
and ROCA
(i) The first difference is that instead of using a latent changepoint structure in the case
model, PMM assumes a linear mixed model with natural cubic splines and additionally
adjusts for the baseline age.
(ii) The second difference lies in the calculation of the cancer diagnosis probability. As
PMM directly models Yi|D1 = 1, the diagnosis probability can be calculated without
marginalization, avoiding the loss of prediction accuracy.
What is more, compared to ROCA, the parameter estimation under PMM could be easily
implemented using standard statistical software packages rather than the Gauss-Hermite
quadrature.
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3.4 SREM for Ovarian Cancer
Under SREM, a linear mixed model with natural cubic splines for the screening time and
the baseline age in a form same as (12) was proposed to simultaneously formulate the case
and the control trajectories. The knot settings of the B-spline basis for the baseline age and
the screening time were determined in the same way as under PMM. For the ovarian cancer
diagnosis prediction, we linked the binary outcome Di to the longitudinal process using a
probit link function P (Di = 1|bi) = Φ(α0 +α1bi0 +α2bi1 +α3bi2 +α4bi3). Under this setting,
the joint likelihood of Yi and Di can be directly obtained from (4). The diagnosis probability
was calculated using (5) with the MLEs of α0, α1, α2, α3, and α4, which were estimated by
the two-stage approach described in Section 2.1.
4 Analysis of the PLCO Ovarian Cancer Data
In this section, ROCA, PMM and SREM were applied to the ovarian cancer example from
the PLCO Cancer Screening Trial.
4.1 The PLCO Ovarian Cancer Data
The ovarian cancer dataset from the PLCO Cancer Screening Trial contains 78215 women
with baseline age between 55 and 74 years at 10 screening centers across the U.S. from 1993
to 2001. Among them, 39104 women were in the intervention arm (receiving up to 6 annual
screenings with CA-125 and 4 annual tests with transvaginal ultrasound) and 39111 in the
control arm (under usual medical care). After the first 6 years of active screening, participants
in both arms were followed for an additional 7 years (Skates et al., 2003; Buys et al., 2011).
Only women in the intervention arm were included in our analyses, since participants in
the control arm did not receive CA-125 screening. Women who met any of the following
criteria were excluded: (i) women who had historical ovarian cancer diagnosis before trial
randomization; (ii) women who had bilateral oophorectomy; (iii) women who received no
CA-125 screening or (iv) ovarian cancer cases who were diagnosed more than three years
after the last screening test. For CA-125 screenings more than three years from the ovarian
cancer diagnosis, they often have flat trajectories that are almost identical to those from
controls. It is hard to tell whether any positive findings in the screening would be indicative
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of ovarian cancer or not (Pinsky et al., 2013). Therefore, cases diagnosed more than three
years from the last screening test were excluded from our analysis. As for the intervention arm
participants chosen as our controls, their follow-up time was similarly truncated to 3 years.
In addition, we removed CA-125 screening results if they were performed after the cancer
diagnosis. Our analytic sample eventually included N = 30402 women. Among them, there
wereM = 133 ovarian cancer cases and 30269 controls. The median numbers of longitudinal
CA-125 measurements were 4 for cases and 6 for controls due to the PLCO trial design. The
ovarian cancer cases were older at the baseline, had fewer CA-125 screenings, and were more
likely to have a family history of ovarian or breast cancer. Additional descriptive statistics
of the PLCO ovarian cancer samples were tabulated in Table S1 in the Supplementary
Material. Pinsky et al. (2013) applied ROCA to the PLCO trial, with the aim of examining
whether ROCA can result in a significant mortality benefit of screening in the intervention
arm compared with the control arm (Pinsky et al., 2013). Our analyses only used the
intervention arm to compare the predictive accuracy of ROCA with PMM and SREM, in
terms of the time-dependent AUC.
4.2 Model Implementation
Different specifications of ROCA case and control models were compared using the likelihood
ratio test, Akaike information criterion (AIC) and Bayesian information criterion (BIC). Risk
scores of each individual under different models were calculated using the leave-one-out cross-
validation (LOOCV) technique to minimize model overfitting: longitudinal CA-125 levels of
each participant were deleted from the dataset in turn, all models were estimated from the
leave-one-out samples, and then the risk score of the excluded individual was calculated
accordingly. Iterating this procedure across all the individuals yielded the out-of-sample
risk prediction. Diagnosis prediction accuracy of the models was compared using the time-
dependent AUC, during 0.5-3 years since the last CA-125 screening. The time-dependent
AUC at a cutoff time t is interpreted as the probability that a randomly selected “case”,
whose cancer diagnosis was before time t, had larger predicted risk than a randomly selected
“control”, whose cancer diagnosis was after time t. The 95% confidence interval (CI) of each
time-dependent AUC was calculated based on 200 bootstrapping replicates. Because of the
LOOCV procedure, the nonparametric bootstrap is computationally forbidden. Therefore,
instead of drawing bootstrap samples with replacement, we drew the bootstrapped parameter
estimates from the fitted asymptotic multivariate normal distributions (R functions were
13
attached in the Supplementary Material).
4.3 Results
The likelihood ratio test for CS1 and CS2 showed that CS2 had better model fitting than
CS1 for the PLCO cases: the negative loglikelihood values for CS1 and CS2 were 387.03 and
330.34, respectively, indicating significant difference (p-value: < 0.0001) (AIC and BIC were
in Table S2 in the Supplementary Material). The fitted parameters of CS1 and CS2 were
reported in Table 1. In CS2, µτ and στ were 1.054 years (95% confidence interval (CI) =
0.978 to 1.130) and 0.314 year (95% CI = 0.234 to 0.394), respectively, substantially different
from the prespecified mean of 2 years and standard deviation of 0.75 year in CS1. The fitted
results of PMM and SREM were in Table S3 in the Supplementary Material.
Table 1: Parameter estimates for CS1 and CS2 based on 133 cases from the PLCO Cancer
Screening Trial: estimate and the 95% confidence interval (CI) were reported.
Parameter CS1 CS2
Estimate (95% CI) Estimate (95% CI)
θ0 2.304 (2.202, 2.406) 2.381 (2.281, 2.481)
γ0 1.352 (1.080, 1.624) 2.365 (1.922, 2.808)
σb0 0.488 (0.404, 0.572) 0.497 (0.423, 0.571)
σb1 1.191 (0.991, 1.391) 1.423 (1.102, 1.744)
ρb0b1 −0.377 (−0.724,−0.030) −0.402 (−0.825,−0.021)
σξ 0.265 (0.240, 0.290) 0.271 (0.246, 0.296)
µτ - 1.054 (0.978, 1.130)
στ - 0.314 (0.234, 0.394)
For controls, the likelihood ratio test revealed that CN2 and CN3 were statistically better
than CN1 with respective p-values < 0.0001 and < 0.0001, whereas there was no significant
difference between CN2 and CN3 (p-value: 0.077) (see Table S2 in the Supplementary Ma-
terial for details). The fitted parameters for all the three control models were reported in
Table 2, which showed that the baseline age and the screening time had small but significant
effects on the CA-125 trajectories. In specific, CN3 indicated that the geometric mean level
of CA-125 increased by 1.92% (95% CI = 1.82% to 2.02%) every year of follow-up, and by
0.2% (95% CI = 0.1% to 0.3%) per 1-year older in the baseline age.
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Table 2: Parameter estimates for CN1, CN2, and CN3 based on 30269 controls from the
PLCO Cancer Screening Trial: estimate and the 95% confidence interval (CI) were reported.
Parameter CN1 CN2 CN3
Estimate (95% CI) Estimate (95% CI) Estimate (95% CI)
θ0 2.337 (2.332, 2.342) 2.296 (2.290, 2.301) 2.158 (2.097, 2.219)
θ1 - 0.019 (0.018, 0.020) 0.019 (0.018, 0.020)
θ2 - - 0.002 (0.001, 0.003)
σb0 0.445 (0.437, 0454) 0.450 (0.441, 0.459) 0.451 (0.442, 0.460)
σb1 - 0.039 (0.009, 0.069) 0.039 (0.008, 0.069)
ρb0b1 - −0.141 (−0.181,−0.101) −0.147 (−0.191,−0.103)
σξ 0.229 (0.224, 0.233) 0.215 (0.211, 0.220) 0.215 (0.211, 0.220)
The comparisons of ROCA, PMM, and SREM with respect to their discrimination abilities
were shown in Table 3: PMM had the highest time-dependent AUCs: 1.8-3.4% higher than
ROCA and 1.6-4.8% higher than SREM across all six cutoff times, while SREM had the
lowest AUCs. The comparison using bootstrapping replicates further showed that PMM
had significantly larger AUCs than ROCA and SREM, whereas there was no significant
difference between SREM and ROCA (details were in the Supplementary Material). Among
different versions of ROCA, more complex case and control models only slightly improved
the time-dependent AUCs at nearly all examined cutoff time points, despite having much
better goodness of fit than the original ROCA. The comparisons over all of the methods
regarding the same setting of case or control model were demonstrated in Figure 2. Figure
2(a)-2(c) illustrated that the improvement in the control model fitting slightly increased the
diagnosis prediction accuracies of ROCA and PMM at almost all cutoff times. For example,
at year 2, the AUC of ROCA-CS1-CN1 was 0.809 (95% CI (0.797, 0.818)), compared to 0.814
(0.802, 0.827) for ROCA-CS1-CN3 that was with a more complicated control model. Figure
2(d)-2(f) showed that more complex case model barely improved the prediction accuracy of
ROCA at all cutoff times. For instance, at year 2, the AUC of ROCA-CS2-CN1 was 0.811
(0.798, 0.817), almost identical to the one of ROCA-CS1-CN1. The advantage of PMM over
ROCA and SREM was displayed in Figure 2(d)-2(f). The AUCs of SREM were very close
to those of ROCA at the beginning of the follow-up period but diminished thereafter. In
addition, we compared the time-dependent ROC curves of the best ROCA (ROCA-CS2-
CN3), the best PMM (PMM-CN3), and SREM across all six cutoff times. As shown in
Figure 3, the ROC curve comparison supported the conclusion that PMM was better than
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ROCA and SREM, and there was no clear advantage of ROCA over SREM, though the
AUCs of ROCA were larger than those of SREM.
Table 3: Time-dependent AUCs of ROCA, PMM, and SREM on analyzing the ovarian cancer
data from the PLCO Cancer Screening Trial. The 95% bootstrapped confidence intervals
were provided.
Method Time-dependent AUC (95% bootstrapped confidence interval)
Year 0.5 Year 1.0 Year 1.5
ROCA-CS1-CN1 0.927 (0.916, 0.933) 0.866 (0.855, 0.873) 0.841 (0.827, 0.850)
ROCA-CS1-CN2 0.928 (0.917, 0.933) 0.868 (0.857, 0.875) 0.845 (0.830, 0.852)
ROCA-CS1-CN3 0.927 (0.916, 0.934) 0.868 (0.857, 0.876) 0.845 (0.829, 0.852)
ROCA-CS2-CN1 0.928 (0.920, 0.935) 0.865 (0.850, 0.869) 0.840 (0.824, 0.846)
ROCA-CS2-CN2 0.928 (0.919, 0.934) 0.866 (0.851, 0.871) 0.842 (0.827, 0.850)
ROCA-CS2-CN3 0.927 (0.918, 0.934) 0.867 (0.851, 0.872) 0.843 (0.827, 0.849)
PMM-CN1 0.946 (0.937, 0.953) 0.892 (0.887, 0.900) 0.863 (0.857, 0.871)
PMM-CN2 0.946 (0.937, 0.954) 0.894 (0.886, 0.902) 0.865 (0.857, 0.872)
PMM-CN3 0.946 (0.937, 0.954) 0.894 (0.886, 0.902) 0.865 (0.858, 0.872)
SREM 0.930 (0.920, 0.938) 0.853 (0.843, 0.862) 0.836 (0.827, 0.844)
Method Year 2.0 Year 2.5 Year 3.0
ROCA-CS1-CN1 0.809 (0.797, 0.818) 0.786 (0.770, 0.796) 0.767 (0.750, 0.773)
ROCA-CS1-CN2 0.813 (0.801, 0.826) 0.789 (0.774, 0.798) 0.772 (0.755, 0.777)
ROCA-CS1-CN3 0.814 (0.802, 0.827) 0.790 (0.774, 0.800) 0.773 (0.755, 0.778)
ROCA-CS2-CN1 0.811 (0.798, 0.817) 0.785 (0.770, 0.796) 0.768 (0.750, 0.773)
ROCA-CS2-CN2 0.814 (0.805, 0.824) 0.789 (0.773, 0.800) 0.772 (0.757, 0.779)
ROCA-CS2-CN3 0.814 (0.805, 0.824) 0.790 (0.773, 0.800) 0.772 (0.757, 0.780)
PMM-CN1 0.837 (0.831, 0.844) 0.816 (0.807, 0.824) 0.797 (0.789, 0.808)
PMM-CN2 0.842 (0.832, 0.851) 0.819 (0.810, 0.828) 0.801 (0.791, 0.809)
PMM-CN3 0.842 (0.832, 0.851) 0.819 (0.810, 0.828) 0.801 (0.791, 0.809)
SREM 0.794 (0.787, 0.801) 0.774 (0.765, 0.782) 0.760 (0.751, 0.768)
5 Simulation Studies
5.1 Simulation Settings
Predictive performances of ROCA, PMM and SREM were further compared in simulation
studies. In order to apply ROCA, both longitudinal and survival information for cases and
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Figure 2: Time-dependent AUC comparisons for ROCA, PMM, and SREM: comparisons
under the same case model setting were in figure (a)-(c) while comparisons under the same
control model setting were in figure (d)-(f).
controls should be simulated. However, as discussed in Section 3.3 and Section 3.4, PMM
and SREM predicted the ovarian cancer diagnosis using CA-125 levels directly. No explicit
dependence relationship between the longitudinal process and the diagnosis time was set
up under PMM and SREM, indicating the diagnosis time simulated from PMM and SREM
would not be informative for the longitudinal observations, and hence can not be used to
fit ROCA. To the contrary, the longitudinal process and the diagnosis time were explicitly
linked together under ROCA.
Two simulation scenarios were considered: Scenario 1 used ROCA-CS2-CN3 as the true
model, whereas Scenario 2 used PMM-CN3 as the true model. We did not pursue the
scenario that SREM is the true data generation model based on the results in Section 4.3
that PMM was superior to SREM. For each simulation, a training dataset of controls and
cases were generated according to the true model. The controls and cases in the training
dataset were used to fit the corresponding control and case models, respectively. Then the
estimated models were applied to a separately generated testing dataset, which also contained
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Figure 3: Time-dependent ROC curve comparisons for ROCA, PMM, and SREM across all
six cutoff time. Only the best ROCA (ROCA-CS2-CN3), the best PMM (PMM-CN3), and
SREM were considered.
the same number of controls and cases as the training dataset. The time-dependent AUCs
from 0.5 to 3 years after the last CA-125 observation were calculated in the testing sample.
In addition, three screening frequencies were considered in the simulations: annual, biannual
and quarterly screening, aiming to examine how the performances of the above models would
be affected by the frequency of CA-125 screening.
To closely mimic the real PLCO ovarian cancer data, particularly the gap time between
the diagnosis time and last screening test associated with each subject, we proposed the
following data generation procedure. Let T ∗i be the unobserved time of the ovarian cancer
diagnosis, and Ci the censoring time. The observed survival time is given by (Ti, Si), where
Ti = min(T
∗
i , Ci) and Si = I(T ∗i < Ci) with I(·) being the indicator function. Let ni be the
cluster size and Yi1, . . . , Yini be the log-transformed CA-125 marker values observed at times
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ti1, . . . , tini , respectively. Let Gi = Ti− tini be the gap time between the last observation and
the end of follow-up. The procedure to generate survival and longitudinal data is given as
follow
1) Step 1: simulate the survival data. The distribution of T ∗i is simulated from an ex-
ponential distribution with rate 6 × 10−4. The distribution of Ci is simulated from
a mixture of two lognormal distributions 1/3LN(1.7, 0.42) + 2/3LN(2.1, 0.162). All
parameter values of the above distributions were obtained by fitting the real PLCO
ovarian cancer data. The censoring time Ci is truncated at 8.9 years as the maximum
follow-up used in this analysis. Results from the PLCO ovarian cancer data showed
that the Kaplan-Meier survival curves were very close to the above fitted parametric
distributions for T ∗i and Ci (see Figure S6 in the Supplementary Material for detail).
2) Step 2: simulate the gap time Gi. The gap time Gi is bounded in [tL, tU ], where
tL = max(0, Ti − 6) and tU = min(3, Ti). This setting is to guarantee that all the
observation times ti1, . . . , tini would be between year 0 and year 6. For each subject i,
we randomly sample one Gi of the participants from the PLCO cancer data that are
bounded in [tL, tU ]. Meanwhile, the associated age of Gi is also chosen as the baseline
age of the ith subject.
3) Step 3: simulate the cluster size ni and the screening time ti1, . . . , tini . Set ni =
bTi−Gic, where bxc denotes the maximum integer not exceeding x. Under the annual
screening setting, the screening time tij = 0, 1, . . . , ni − 1, so that the biomarker is
screened annually from year 0 to year ni − 1. The cluster size and the screening time
under the settings of biannual and quarterly screening can be set similarly. In specific,
under the biannual screening, the size is 2ni− 1 and the time is tij = 0, 0.5, . . . , ni− 1,
while they are 4ni − 3 and tij = 0, 0.25, 0.5, . . . , ni − 1 under the quarterly screening.
4) Step 4: simulate the log-transformed CA-125 values using ROCA-CS2-CN3 or PMM-
CS3 based on the above simulated screening time, the diagnosis time, the event status,
and the baseline age.
Under Scenario 1, both training and testing datasets were set to contain 1000 controls and
500 cases. While under Scenario 2, the total number of controls and cases was 30402 in both
the training and testing datasets. Details about the simulation setting and an R function
were provided in the Supplementary Material.
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Simulation results under Scenario 1 were reported in Table 4. When the annual screening
scheme was simulated (same as the PLCO ovarian cancer data), the differences among all
ROCAs were small, but in general ROCA-CS2-CN3 had the best performance regarding
diagnosis prediction, almost identically followed by ROCA-CS2-CN2. ROCA outperformed
PMM and SREM over all cutoff time points, while SREM had the least satisfactory perfor-
mance. As the number of CA-125 screenings increased, the predictive advantage of ROCA
over PMM and SREM became more prominent. This is because more data points near the
CA-125 changepoint became available to precisely estimate the latent changepoint struc-
ture of ROCA. To the contrary, the predictive performances of SREM deteriorated as the
number of the screened CA-125 measurements increased, as the difference between case and
control trajectories became evident. The discriminative accuracy of PMM did not change
much.
When PMM-CN3 was the true model, Table 5 showed that PMM outperformed ROCA
and SREM. For both ROCA and PMM, complicated case or control models only provided
a small amount of improvements to the time-dependent AUCs. SREM still had the least
satisfactory performances. As the number of CA-125 screenings increased, all methods had
improved values for the time-dependent AUC.
6 Discussion
In this paper, we focused on the problem of predicting disease early detection using longitu-
dinal biomarker measurements. Two general disease risk prediction frameworks, the shared
random effects model (SREM) (Albert, 2012) and the pattern mixture model (PMM) (Liu
and Albert, 2014) were considered. We showed that SREM and PMM can be applied to
disease early detection in a general setting, though they were developed in a very different
situation of disease risk prediction. We examined and evaluated the utility of SREM and
PMM for disease early detection through an application to the early detection of ovarian
cancer from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
The predictive performances of SREM and PMM were compared with the risk of ovarian
cancer algorithm (ROCA), which is specifically proposed for ovarian cancer early detection
(Skates et al., 2001). Specific formulations of SREM and PMM for predicting ovarian cancer
early detection were provided. We also extended ROCA by estimating the latent change-
point structure and considering the effects of the screening time and the baseline age on the
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development of the biomarker trajectory. The predictive performances of the above three
methods were assessed using the time-dependent AUC (Heagerty et al., 2000), such that
the censored cancer diagnosis time information can be incorporated into the AUC calcula-
tion. We additionally studied the effects of three biomarker screening frequencies (annual,
biannual, and quarterly) on model prediction accuracy via simulations.
In the PLCO ovarian cancer data analysis, we found that PMM significantly outperformed
ROCA and SREM. Though ROCA had slightly larger AUC values than SREM, it did not
significantly differ from SREM. We noticed that a design of the PLCO trial may affect the
AUC values we presented: in the intervention arm, CA-125 was used to manage women, i.e.,
they were referred to diagnostic evaluation when CA-125 was elevated. Therefore, the AUC
based on CA-125 may be overestimated under this setting. However, such design would not
affect the comparison pattern of the above approaches. The comparison is interesting as
ROCA is more biologically sensible for modeling the “jump-up” pattern in the case marker
trajectories shown in Figure 1. One explanation is the way that ROCA implements the
prediction. ROCA models the marker profiles using unobserved changepoints conditioning
on the cancer diagnosis time, which is unknown when it comes to predict the cancer on-
set for a new individual. To calculate the detection probability, ROCA needs to estimate
the joint distribution of the longitudinal marker profiles by marginalizing out the diagnosis
time. However, this marginalization may result in loss of prediction accuracy, especially
when the sample size of the cases is relatively small. In addition, the estimation of the latent
changepoint structure may suffer from sparse measurements around the changepoint under
the annual screening design of CA-125 in the PLCO trial. We found from the simulation
studies that the performance of ROCA could be substantially improved with more frequent
screening data. To the contrary, SREM and PMM directly estimated the CA-125 distribu-
tion independently from the cancer diagnosis time and used natural splines to model the
nonlinear marker trajectories, avoiding the difficulty in estimating the latent changepoint.
The changepoint pattern also exists in other cancer studies, for example, prostate cancer,
(Barry, 2001), where the level of the biomarker prostate-specfic-antigen would be elevated
before a prostate cancer case is diagnosed. This hence indicates the general applicability of
SREM and PMM to disease early detection.
Extensions to the case and the control models in the original ROCA were proposed. We
found that these extensions resulted in better model fitting, but only slightly improved the
predictive performance of ROCA, both in the PLCO data analysis and in simulation studies.
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There may be several explanations of this result. First, as a rank-based measure, AUC is
difficult to improve, unless the rankings of the calculated risk differ dramatically. Second, the
latent changepoint structure is hard to estimate precisely with only few observations around
the changepoint, and hence extending the case model with flexible changepoint distribution
may not substantially change the risk calculation. Third, as the screening time and the
baseline age only have small effects on the longitudinal CA-125 trajectory, incorporating
them in the control model may not strongly affect the risk calculation either.
The performance of SREM was not as good as PMM or ROCA, possibly due to that SREM
models the CA-125 trajectories of both cases and controls simultaneously. This simultaneous
modeling may not be a sensible choice, especially when the case trajectories are evidently
different from the control ones, as shown by the ROCA simulation results in Table 4 under
the setting of quarterly screening. Furthermore, SREM may need to formulate the shared
random effects and the outcome in a more complicated way rather than using a simple linear
relation, calling for future methodological development.
In our study, the comparison on the discriminative performances of SREM, PMM, and ROCA
on predicting the ovarian cancer early detection was based on a single biomarker CA-125,
which was annually screened in the PLCO Cancer Screening Trial. Several biomarkers have
been recently reported for the early detection of ovarian cancer, and studies show that
incorporating those biomarkers may help to gain better prediction accuracy (Zhang et al.,
2004; Russell et al., 2017; Visintin et al., 2008). For example, Russell et al. (2017) propose a
risk prediction method for ovarian cancer by adopting three additional biomarkers together
with CA-125 and demonstrate that their method has better discriminative performance
than ROCA. As ROCA models CA-125 only, it cannot handle multiple biomarkers. To the
contrary, as general frameworks for disease risk prediction of longitudinal studies, PMM and
SREM can be easily extended to deal with studies that are with multiple biomarkers (Liu and
Albert, 2014; Zhang et al., 2012), resulting in a possible solution to predict the early detection
of ovarian cancer using the recently reported markers. However, using multiple longitudinal
biomarkers can be computationally challenging and requires further research.
ROCA, PMM and SREM were all constructed with the binary outcome (cancer and non-
cancer) but did not fully utilize the cancer diagnosis time. Therefore, the risk calculation
cannot provide an absolute risk estimation, i.e., t-year cancer-free survival since the last CA-
125 screening. Our future investigations will focus on the extensions of the above mentioned
methods to handle the survival outcome.
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In conclusion, our study shows that SREM and PMM can be applied to disease early detec-
tion in the general setting of longitudinal studies, though they were originally developed for
disease risk prediction. Analysis of the ovarian cancer data from the PLCO Cancer Screening
Trial finds that using PMM to predict the early detection of ovarian cancer under an annual
screening setting significantly outperforms ROCA and SREM. The proposed extensions to
the case and the control models in the original ROCA can significantly improve the model
fitting but not necessarily the prediction accuracy. The early detection prediction accuracy of
ROCA could be improved with more frequent CA-125 screenings, as the latent changepoint
structure would be better estimated accordingly.
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